Prestige BioPharma Limited (KRX:950210)
South Korea flag South Korea · Delayed Price · Currency is KRW
6,880.00
+40.00 (0.58%)
Aug 12, 2026, 2:40 PM KST

Prestige BioPharma Cash Flow Statement

Millions KRW. Fiscal year is Jul - Jun.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Net Income
-57,32122,297-32,92117,569-211,450-7,391
Depreciation & Amortization
21,80121,80116,26711,6503,8671,667
Loss (Gain) From Sale of Assets
6.76.7-89.4-55.17-266.370.36
Asset Writedown & Restructuring Costs
-59,462-59,462-15,11472,607-
Loss (Gain) From Sale of Investments
---693.3918,966-15,081
Stock-Based Compensation
470.11470.1152.411,9433,7742,955
Provision & Write-off of Bad Debts
---33.31-70,640--
Other Operating Activities
58,856-31,684-42,356-17,82685,640330.51
Change in Accounts Receivable
-228.75-228.75674.94-1,050--
Change in Inventory
-4,764-4,7647,752-10,038-24,041-
Change in Accounts Payable
4,1964,1962,459-316.41,641-
Change in Unearned Revenue
-310.36-310.36-5.21-660.52564.62578.1
Change in Other Net Operating Assets
-4,456-4,456172.41-6,6582,7911,495
Operating Cash Flow
-41,214-52,135-48,027-60,274-45,907-15,446
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Capital Expenditures
-16,321-40,742-20,063-48,363-56,429-949.11
Sale of Property, Plant & Equipment
100.0894.251.211,13326,428-
Divestitures
---40,039--
Sale (Purchase) of Intangibles
-8,701-6,028-7,463-17,254-11,684-17,162
Investment in Securities
54,131-53,291159,987-133,827-25,239-
Other Investing Activities
-2,121-1,840-46.859,66212,555-2,801
Investing Cash Flow
27,088-101,806132,465-148,610-184,685-20,912

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Long-Term Debt Issued
-53,319-55,772-2,769
Long-Term Debt Repaid
--5,474-2,771-2,589-4,504-895.88
Net Debt Issued (Repaid)
-69,14547,846-2,77153,183-4,5041,873
Issuance of Common Stock
1,1171,1171,307--466,094
Other Financing Activities
1,169901.41----13,450
Financing Cash Flow
-66,85949,864-1,46453,183-4,504454,517

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Foreign Exchange Rate Adjustments
1,0631,850608.726,888-3,177-277.54
Miscellaneous Cash Flow Adjustments
---0000
Net Cash Flow
-79,921-102,22883,582-148,813-238,273417,880

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Free Cash Flow
-57,535-92,877-68,091-108,636-102,336-16,396
Free Cash Flow Growth
------
Free Cash Flow Margin
-354.94%-648.33%-9881.47%-67125.45%--
Free Cash Flow Per Share
-957.00-1542.04-1135.49-1807.71-1702.88-317.73
Levered Free Cash Flow
-74,417-122,563-46,364-23,046-114,523-22,341
Unlevered Free Cash Flow
-69,651-117,797-41,736-22,451-114,511-22,337

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Cash Interest Paid
3,17210,7426,0821,834436.07477.47
Cash Income Tax Paid
56.79-37.32-179.73796.41591.8234.08
Change in Working Capital
-5,563-5,56311,053-18,723-19,0442,073